Ryan & Maniskas, LLP Announces Investigation of Catalyst Pharmaceuticals, Inc.

WAYNE, Pa., Feb. 26, 2016

Catalyst shareholders who purchased shares should contact Richard A. Maniskas, Esquire at 877-316-3218 or at rmaniskas@rmclasslaw.com to learn more about this investigation or visit: www.rmclasslaw.com/cases/cprx.      

The investigation concerns whether Catalyst and certain of its officers and/or directors have violated Sections 10(b) and 20(a) of the Securities Exchange Act of 1934.

On February 17, 2016, pre-market, Catalyst announced that the Company has received a "Refusal To File" letter from the U.S. Food and Drug Administration regarding its New Drug Application for Firdapse (amifampridine phosphate). The "Refusal to File" letter states that after a preliminary review, the FDA has found that the application, which was submitted in December 2015, was not sufficiently complete, and requests additional supporting information. The letter does not provide comment on the acceptability of the submitted clinical data, and no judgment is made in the letter on the efficacy or safety of Firdapse.

On this news, Catalyst stock has fallen as much as $0.92 per share, or nearly 50%, to $0.93 per share during intraday trading on February 17, 2016.

If you own Swift shares and would like to learn more about these claims or if you wish to discuss these matters and have any questions concerning this announcement or your rights, contact Richard A. Maniskas, Esquire toll-free: (877) 316-3218 or visit: www.rmclasslaw.com/cases/cprx.  You may also email Mr. Maniskas at rmaniskas@rmclasslaw.com.  For more information about class action cases in general, please visit our website: www.rmclasslaw.com.

Ryan & Maniskas, LLP is a national shareholder litigation firm.  Ryan & Maniskas, LLP is devoted to protecting the interests of individual and institutional investors in shareholder actions in state and federal courts nationwide.